Abstract
Objective To preliminary investigate the clinical efficacy of whole brain simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) in patients diagnosed with brain metastases (BM). Methods Fifty-two cases of BM admitted to our hospital from January 2016 to December 2017 were equally recruited and randomly divided into the observation and control groups. Patients in the observation group were treated with SIB-IMRT, and those in the control group received conventional whole brain radiotherapy (WBRT). The clinical efficacy and prognosis were statistically compared between two groups. Results The ORR in the observation group was 77%, significantly higher than 27% in the control group (P=0.00). The median survival in the observation group was 384 d, significantly longer compared with 211 d in the control group (P=0.00). All patients in both groups successfully completed corresponding treatment. Acute adverse reactions were mainly 1-2 grade reactions. Conclusions SIB-IMRT is an efficacious and safe treatment of BM, which yields tolerable adverse events and deserves application in clinical practice. Key words: Neoplasms metastasis, brain/whole brain simultaneous integrated boost intensity-modulated radiotherapy; Neoplasms metastasis, brain/whole brain radiotherapy; Treatment outcome
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
